2.12

0.47% -0.010

After Hours: 2.12

CytoMed Therapeutics Ltd (GDTC)

Overview News Price History Discussions Forecast

CytoMed Therapeutics Ltd stock is currently priced at $2.12, with a 24-hour trading volume of 5,344. It has seen a -0.47% decreased in the last 24 hours and a +2.42% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $2.17 pivot point. If it approaches the $2.09 support level, significant changes may occur.

Previous Close:

$2.13

Open:

$2.13

24h Volume:

5,344

Market Cap:

$24.46M

Revenue:

Net Income/Loss:

$-3.15M

P/E Ratio:

-10.25

EPS:

-0.2069

Net Cash Flow:

$-2.23M

1W Performance:

-0.47%

1M Performance:

+2.42%

6M Performance:

-43.01%

1Y Performance:

-30.72%

1D Range:

$2.12

$2.13

52W Range:

$1.92

$9.25

CytoMed Therapeutics Ltd Stock (GDTC) Company Profile

Name

CytoMed Therapeutics Ltd

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

65 6250 7738

Address

1 Commonwealth Lane, No. 08-22, Singapore

Employee

Twitter

Next Earnings Date

Latest SEC Filings

GDTC's Discussions on Twitter

CytoMed Therapeutics Ltd Stock (GDTC) Latest News

Wall Street Breakfast: The Week Ahead

Seeking Alpha

CytoMed Diversifies into Regenerative Medicine after Research Collaboration with Singapore's Sengkang General ... - Yahoo Finance

Yahoo Finance

CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies

GlobeNewswire Inc.

CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair

GlobeNewswire Inc.

CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to ... - Yahoo Finance

Yahoo Finance

Why Container Store Group Shares Are Trading Lower By Around 23%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Benzinga

CytoMed Therapeutics Ltd Stock (GDTC) Financials Data

CytoMed Therapeutics Ltd (GDTC) Net Income 2024

GDTC net income (TTM) was -$3.15 million for the quarter ending June 30, 2023.

CytoMed Therapeutics Ltd (GDTC) Cash Flow 2024

GDTC recorded a free cash flow (TTM) of -$2.23 million for the quarter ending June 30, 2023.

CytoMed Therapeutics Ltd (GDTC) Earnings per Share 2024

GDTC earnings per share (TTM) was -$0.3052 for the quarter ending June 30, 2023.

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. The company was incorporated in 2018 and is headquartered in Singapore. CytoMed Therapeutics Limited operates as a subsidiary of Glorious Finance Ltd